Status and phase
Conditions
Treatments
About
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Acyclovir 800 mg Tablet and Reference Product (Zovirax™) in Healthy Thai Volunteers under Fasting Conditions
Full description
This study is conducted to investigate bioequivalence information which is required to ensure therapeutic equivalence of a test product and a reference product as well as to be considered as one aspect of product quality. Bioequivalence is defined as the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.
The manufacturer in Thailand needs to formulate a generic acyclovir 800 mg tablet. This study has been planned to evaluate the pharmacokinetics of this formulation and determine its bioequivalence with the reference product, Zovirax™, at the same dose.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
IInclusion Criteria
Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups
Loading...
Central trial contact
Nannapat Wannaphruek; thanaporn Wongyai
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal